MaxCyte’s (MXCT's) deal with clinical-stage industry leader Allogene Therapeutics (ALLO) is a clear endorsement of the features of its Flow Electroporation technology for enabling the production of the next generation of ‘off-the-shelf’ CAR-T therapies. Not only is this an impressive deal since ALLO is a landmark company in the field, but it also counts an array of scientific experts including ose who led the launch of Yescarta at Kite/Gilead, the second CAR-T therapy approved by the US Food & Drug Administration (FDA). Described by Allogene as the ‘industry standard’, MXCT’s Flow Electroporation has been chosen to improve yield and efficiency of its lead clinical programmes. This is critical to help fulfil the promise of such off-the-shelf treatments that can reach many more patients, much more quickly than first-gen CAR-T therapies, providing potentially curative outcomes in cancers as well as rare diseases.